GlassScriptPhysician profile
William V Irby
NPI 1902874779
$3,674.73
in general payments reported to CMS, 2019-2025
28 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.00 · 2020: $51.44 · 2021: $223 · 2022: $500 · 2023: $1,053 · 2024: $1,040 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.10 | 2021-2025 | |
| Lilly USA, LLC | $504.05 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $406.62 | 2022-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $314.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $233.59 | 2023-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $233.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $143.12 | 2022-2023 | Livalo, Seglentis |
| Mylan Specialty L.P. | $137.70 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $137.31 | 2023-2024 | |
| Dexcom, INC. | $133.33 | 2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $110.44 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $105.46 | 2021-2024 | Vaxelis, Vaxneuvance, Capvaxive |
| Lundbeck LLC | $101.51 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.02 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $64.15 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.35 | 2022-2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $31.50 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.76 | 2022 | |
| Sumitomo Pharma America, INC. | $21.17 | 2024 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $19.03 | 2025 | |
| Viiv Healthcare Company | $18.03 | 2024 | Dovato |
| Allergan, INC. | $15.73 | 2020 | |
| Philips North America LLC | $15.70 | 2021 | |
| Exact Sciences Corporation | $15.00 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.09 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $13.90 | 2021 | |
| Genentech USA, INC. | $12.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Irby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.